[文集] [专题] [检索] [独立评论] [海阔天空] [矛盾江湖] [全版论坛]

独立评论

作者: cwing   华邮:柳叶刀撤回"羟喹高險"論文,衛報:該論文數據提供方背景反常 2020-07-26 01:32:41  [点击:2313]
自從武漢肺炎爆發以來,關於羟氯喹的爭論一直存在
川普力挺羟氯喹療效,
医学顶级期刊柳叶刀适时發表的一篇證明羟氯喹高風險高致死率的文章,給予挺川一派迎頭痛擊
不過後來华邮報道,柳叶刀撤回了那篇"羟喹高險"論文,
左報衛報對這篇論文的數據提供方進行了人肉,
這家芝加哥(奧巴馬家鄉)的數據公司為多项Covid-19研究提供数据,但迄今未能充分解释其数据或方法論,其背後可能涉及的數據造假問題駭人聽聞
但最有趣味的還是這家公司本身
根據衛報的背景調查
這家小公司(领英雇员列表最多時衹有六人,后又變爲3人,实际可能更少)
其中科學編輯一職由一位全職科幻作家担任
而營銷女主管是一位成人視訊演員

关于羟氯喹的疗效還沒有定論還在爭論
不同团队研究的结果不同,有说有效的有说无效的
但这是科学问题
科学问题顯然不能通過来源不明數據和論文“大躍進”來解決
--------------------------------------------
作者: cwing "卫报:疑器官被活摘,吁撤回400陆医学论文,ieee拒华为很利索" 改贴 2019-06-04 20:07:57 [点击:1053]
http://duping.net/XHC/show.php?bbs=10&post=1418546
作者: cwing "卫报:班农自称列宁主义者.班农:犹太基督之敌是两种资本主义" 改贴 2019-04-19 00:47:19 [点击:11296]
http://duping.net/XHC/show.php?bbs=10&post=1417307
------------------------------------------
https://www.theguardian.com/world/2020/jun/03/covid-19-surgisphere-who-world-health-organization-hydroxychloroquine
Surgisphere: governments and WHO changed Covid-19 policy based on suspect data from tiny US company
This article is more than 1 month old

Surgisphere, whose employees appear to include a sci-fi writer and adult content model, provided database behind Lancet and New England Journal of Medicine hydroxychloroquine studies

Melissa Davey in Melbourne and Stephanie Kirchgaessner in Washington and Sarah Boseley in London

Wed 3 Jun 2020 14.47 EDT
First published on Wed 3 Jun 2020 06.54 EDT

A tiny US company, Surgisphere, is behind flawed data which led to governments and the world health organisation changing health policy
A tiny US company, Surgisphere, is behind flawed data which led to governments and the world health organisation changing health policy Photograph: Anthony Brown/Alamy Stock Photo

The World Health Organization and a number of national governments have changed their Covid-19 policies and treatments on the basis of flawed data from a little-known US healthcare analytics company, also calling into question the integrity of key studies published in some of the world’s most prestigious medical journals.

A Guardian investigation can reveal the US-based company Surgisphere, whose handful of employees appear to include a science fiction writer and an adult-content model, has provided data for multiple studies on Covid-19 co-authored by its chief executive, but has so far failed to adequately explain its data or methodology.

Data it claims to have legitimately obtained from more than a thousand hospitals worldwide formed the basis of scientific articles that have led to changes in Covid-19 treatment policies in Latin American countries. It was also behind a decision by the WHO and research institutes around the world to halt trials of the controversial drug hydroxychloroquine. On Wednesday, the WHO announced those trials would now resume.

Two of the world’s leading medical journals – the Lancet and the New England Journal of Medicine – published studies based on Surgisphere data. The studies were co-authored by the firm’s chief executive, Sapan Desai.

Late on Tuesday, after being approached by the Guardian, the Lancet released an “expression of concern” about its published study. The New England Journal of Medicine has also issued a similar notice.

An independent audit of the provenance and validity of the data has now been commissioned by the authors not affiliated with Surgisphere because of “concerns that have been raised about the reliability of the database”.
Questions raised over hydroxychloroquine study which caused WHO to halt trials for Covid-19
Read more

The Guardian’s investigation has found:

A search of publicly available material suggests several of Surgisphere’s employees have little or no data or scientific background. An employee listed as a science editor appears to be a science fiction author and fantasy artist whose professional profile suggests writing is her fulltime job. Another employee listed as a marketing executive is an adult model and events hostess, who also acts in videos for organisations.

The company’s LinkedIn page has fewer than 100 followers and last week listed just six employees. This was changed to three employees as of Wednesday.


While Surgisphere claims to run one of the largest and fastest hospital databases in the world, it has almost no online presence. Its Twitter handle has fewer than 170 followers, with no posts between October 2017 and March 2020.

Until Monday, the “get in touch” link on Surgisphere’s homepage redirected to a WordPress template for a cryptocurrency website, raising questions about how hospitals could easily contact the company to join its database.

Desai has been named in three medical malpractice suits, unrelated to the Surgisphere database. In an interview with the Scientist, Desai previously described the allegations as “unfounded”.

In 2008, Desai launched a crowdfunding campaign on the website Indiegogo promoting a wearable “next generation human augmentation device that can help you achieve what you never thought was possible”. The device never came to fruition.

Desai’s Wikipedia page has been deleted following questions about Surgisphere and his history, first raised in 2010.

Sapan Desai
Facebook Twitter
Pinterest
Sapan Desai, the chief executive of Surgisphere. Photograph: Gore Medical

At a press conference on Wednesday, the WHO announced it would resume its global trial of hydroxychloroquine, after its data safety monitoring committee found there was no increased risk of death for Covid patients taking it.

The WHO director general, Dr Tedros Adhanom Ghebreyesus, said that all parts of the Solidarity trial, which is investigating a number of potential drug treatments, would go ahead. So far, more than 3,500 patients have been recruited to the trial in 35 countries.

“On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol,” said Tedros. “The executive group received this recommendation and endorsed continuation of all arms of the Solidarity trial, including hydroxychloroquine.”
Doubts over Lancet study

Questions surrounding Surgisphere have been growing in the medical community for the past few weeks.

On 22 May the Lancet published a blockbuster peer-reviewed study which found the antimalarial drug hydroxychloroquine, which has been promoted by Donald Trump, was associated with a higher mortality rate in Covid-19 patients and increased heart problems.

Trump, much to the dismay of the scientific community, had publicly touted hydroxychloroquine as a “wonder drug” despite no evidence of its efficacy for treating Covid-19.

The Lancet study, which listed Desai as one of the co-authors, claimed to have analysed Surgisphere data collected from nearly 96,000 patients with Covid-19, admitted to 671 hospitals from their database of 1,200 hospitals around the world, who received hydroxychloroquine alone or in combination with antibiotics.

The negative findings made global news and prompted the WHO to halt the hydroxychloroquine arm of its global trials.
----------------------------------
https://www.washingtonpost.com/health/2020/06/04/researchers-retract-study-that-found-big-risks-using-hydroxychloroquine-treat-covid-19/
Researchers retract study that found big risks in using hydroxychloroquine to treat covid-19
Study authors say they can’t vouch for the data they used.
Researchers retracted a controversial study in the Lancet purportedly showing that hydroxychloroquine posed big safety risks for covid-19 patients. (AP/David J. Phillip)
Researchers retracted a controversial study in the Lancet purportedly showing that hydroxychloroquine posed big safety risks for covid-19 patients. (AP/David J. Phillip)
By
Laurie McGinley
June 4, 2020 at 6:36 PM EDT

Three of the authors of a study that found the antimalarial drug hydroxychloroquine was dangerous for hospitalized covid-19 patients retracted it Thursday, saying they could “no longer vouch for the veracity of the primary data sources.”

The retraction notice was posted by the medical journal Lancet, which had published the study on May 22.

The study, purportedly based on the health records of almost 100,000 patients around the world, found that hospitalized covid-19 patients treated with the antimalarial drug hydroxychloroquine — a drug repeatedly touted by President Trump — had a sharply higher risk of death and heart problems compared to those who did not receive the drug. It also showed the drug didn’t provide a benefit. The study was “observational,” which is less rigorous than a randomized, placebo-controlled clinical trial.
AD

Almost immediately after the study’s publication, critics raised questions about the data and analysis provided by a private company, Chicago-based Surgisphere, and its founder, Sepan Desai. Another study that also relied on the database — one that looked at the effects of blood-pressure medications on covid-19 patients — also was retracted Thursday, by the New England Journal of Medicine.

Desai, who was listed as one of four authors on the study, was not immediately available to comment.

The retractions raised concerns in the medical and scientific community that researchers and even prestigious medical journals are lowering their standards in a rush to publish during the pandemic.

“I’m concerned that the usual standards, both at the level of the journals and at the level of authors and faculty rushing to get high-impact work published, has meant that our usual standards have fallen,” said Steven Joffe, a medical ethicist at the University of Pennsylvania.
AD

“Everybody should be stopping and pausing and asking: ‘Are we moving too quickly; are we confident in the quality of our data, and our analysis?’ ” he added. “There is a need for caution and scrutiny at every level of the process.”

Controversy surrounding hydroxychloroquine and a related drug, chloroquine, has swirled for months, partly because Trump has urged people to try the drugs and has taken hydroxychloroquine himself, even in the absence of a clear benefit. The Food and Drug Administration has warned that the drug can cause heart problems and urged that it be used only in hospital settings or clinical trials.

The Lancet retraction is unlikely to quell the controversy about the drug. On Wednesday, researchers at the University of Minnesota Medical School on Wednesday reported the results of a randomized, placebo-controlled trial, saying the drug was no better at preventing covid-19 than a placebo. Additional randomized trials, considered the gold standard, are being conducted.
AD

The authors of the Lancet study said in their statement that they launched an independent third-party peer review of Surgisphere, with the consent of Desai, to confirm the completeness and accuracy of the data and to replicate its analysis.

But, they said, the company declined to provide the full data set to the reviewer, saying it would violate client agreements and confidentiality requirements.

“As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process,” said the statement by the lead author, Mandeep R. Mehra, a Harvard Medical School professor and physician at Brigham and Women’s Hospital, and two other authors.

The authors apologized to the editors of the journal and its readers for causing “any embarrassment or inconvenience.”

The study had a major impact, prompting the World Health Organization to temporarily suspend use of hydroxychloroquine in a clinical trial on covid-19 treatments, and France banned its use in covid-19 patients.
最后编辑时间: 2020-07-26 01:54:07

加跟贴

笔名:     新网友请先注册笔名 密码:
主题: 进文集
内容: